The PhenoImager Solution

Spatial Signatures at Scale

We’ve rebranded some of our products, learn more ›

CODEX is now PhenoCycler
Phenoptics is now Phenolmager

PhenoImager – Rapid, accurate spatial phenotyping

Unraveling the complex and dynamic tumor microenvironment requires the assessment of spatial relationships between tumor and immune cells. Multiplex imaging utilizing tumor and immunologic markers can reveal the spatial relationships between tumor and immune cells, leading to the discovery of spatial signatures, a new class of highly predictive biomarkers that measure the interactions and cellular densities of tumor and immune cells that compose the tumor microenvironment.

Our PhenoImager® Instruments, powered by patented Multispectral Imaging (MSI) Technology, are the fastest quantitative digital pathology imaging platforms enabling rapid and accurate spatial phenotyping at scale.

Pave the path for spatial signatures with your team using the PhenoImager and the newly launched PhenoCode™ Signature Panels.

Benefits

icon-speed

Fast

Fastest Spatial Phenotyping Imagers in the world
icon-data

Accurate

Patented MSI Technology Enables Quantitative Spatial Phenotyping
icon-workflow

Integrated

Integrated Multiplex Immunofluorescence Imaging Solution Optimized from Sample to Result
icon-optimization

Efficient

Get More Data by Multiplexing While Saving Precious Samples

Case Studies

phenoimager-casestudy1
First Multi-Institutional Analytical Demonstration of a Spatial Biology Workflow
The MITRE study, published in the Journal for Immunotherapy of Cancer, established the high reproducibility and robustness of Akoya Biosciences’ PhenoImager multiplex imaging platform for spatial phenotyping in clinical research.

Top immuno-oncology and pathology experts from five institutions collaborated with Akoya to conduct the MITRE study, including Johns Hopkins University School of Medicine, Yale University School of Medicine, Earle A. Chiles Research Institute, The University of Texas MD Anderson Cancer Center, and Bristol Myers Squibb.
Spatial Biomarkers in Immuno-Oncology: Recent Developments and Future Directions
In this four-part webinar series, researchers discuss pioneering new strategies representing significant milestones that advance Spatial Biology into the realm of patient phenotyping and improving immunotherapy outcomes in the future. Hear from our expert panel on recent developments that establish the vital role of Spatial Biomarkers in setting the future directions in achieving Precision Immuno-Oncology.
Investigating-Tertiary-Lymphoid
Investigating Tertiary Lymphoid Structures in Solid Tumors
Learn how researchers used mutliplex immunofluorescence to study tertiary lymphoid structures and discover their prognostic and predictive relevance in cancer.

Imaging Gallery

Technology

MSI-Technology-Image

Watch this video to learn about how the PhenoImager instruments use a patented Multispectral Imaging (MSI) Technology and spectral unmixing to isolate autofluorescence and biomarkers of interest regardless of their intensity or any spectral overlap into separate channels, providing accurate and quantitative data for spatial phenotyping applications.

Workflow

Related Publications

Immune infiltrate dynamics and response to chemotherapy in breast cancer
2021 Aug 12
West German Study Group researchers utilize multiplexed imaging to predict response to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC).
Role of tertiary lymphoid structures (TLSs) in response to immunotherapy
2021 Aug 20
University of Bordeaux team applies multiplex immunofluorescence imaging to identify mature TLSs within several solid tumors and show their association with better outcomes for cancer patients treated with immunotherapy.
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
2022 May 26
Teams from the University of Bordeaux and Sorbonne University in a prospective trial study applied multiplex immunofluorescence imaging to study intratumoral tertiary lymphoid structures (TLSs) which are associated with improved outcomes in patients with soft-tissue sarcomas (STS) which show limited clinical benefit to immune checkpoint inhibitors (ICIs) .

Get in touch with us

Technical Support

An Akoya technical expert is happy to help, contact us today!

Contact a Representative

We are happy to answer any questions you have about our platforms, technology and services.